Categories: All postsAnalysts

It’s a good time to buy Kinaxis stock, Laurentian Bank Financial says

Kinaxis CEO John Sicard

Kinaxis (Kinaxis Stock Quote, Chart TSX:KXS) remains a high quality top line growth story, says Laurentian Bank Securities analyst Nick Agostino who in a Thursday action note to clients reiterated his “Buy” recommendation and target price of C$105.00.

for KXS, representing a projected return of 18.1 per cent at the time of publication.

Ahead of Kinaxis’ third quarter financials on November 9, Agostino expects KXS to generate in-line results on sales at $39.5 million, EBITDA of $10.5 million and adj. EPS of $0.23 (all figures in US dollars unless otherwise noted). Drilling down, the analyst is looking for subscription sales of $28.4 million with the company ending Q3 with $175.0 million in net cash.

Agostino says that he’ll be focusing on three main items driving his growth expectations: (1) continued momentum in Kinaxis’ Life Sciences/Autos segments; (2) market penetration in consumer packaged goods; and (3) increased penetration into a new vertical, viz. process manufacturing.

“From our observations at the User Conference, we believe Life Sciences, CPG, High Tech, and Food & Beverage remain solid growth areas for KXS based on client and prospect attendees/feedback,” says Agostino.

The analyst bases his target price on a 9x his 2019/2020 sales estimate valuation.

“As witnessed in the past, management has a track record of raising guidance as the year plays out, and as contract visibility improves. Given the momentum evident at the User Conference and the upped guidance in Q2, we see a similar potential as 2018 firms up,” he says. “In light of the recent market sell-off and with KXS’s growth trajectory on solid ground, we believe an attractive entry point is before investors.”

Tagged with: kxs
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

WELL Health’s headwinds are in the “rearview mirror”, analyst says

Stifel analyst Justin Keywood said in an April 23 update that management commentary from WELL Health Technologies (WELL Health Technologies… [Read More]

2 days ago

Why this investor likes Taiwan Semiconductor right now

iA Global Asset Management portfolio manager Dan Rohinton told BNN Bloomberg’s Market Call on April 21 that Taiwan Semiconductor  (Taiwan… [Read More]

2 days ago

EQB is a buy following “fantastic” merger, this investor says

Kingwest & Company managing director Tim Regan told BNN Bloomberg’s Market Call on April 20 that EQB (EQB Stock Quote,… [Read More]

2 days ago

National Bank just cut its target on this Canadian airline stock

National Bank of Canada Capital Markets analyst Cameron Doerksen said in a note ahead of Cargojet’s (Cargojet Stock Quote, Chart,… [Read More]

3 days ago

Buy Calix stock? Here’s what this analyst says

Roth Capital analyst Scott Searle reiterated a “Buy” rating and $85.00 12-month price target on Calix (Calix Stock Quote, Chart,… [Read More]

3 days ago

Canadian tech stocks are perking up, this analyst says

In an April 20 sector update, Paradigm Capital analyst Daniel Rosenberg said small-cap technology is showing signs of a risk… [Read More]

3 days ago